Curcumin Induces Pro-apoptotic Effects Against Human Melanoma Cells and Modulates The Cellular Response to Immunotherapeutic Cytokines

per Bill, Matthew A., Bakan, Courtney, Benson, Don M., Fuchs, James, Young, Gregory, Lesinski, Gregory B.
Publicat 2009

A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells

per Lin, Li, Benson, Don M., DeAngelis, Stephanie, Bakan, Courtney E., Li, Pui-Kai, Li, Chenglong, Lin, Jiayuh
Publicat 2011

Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma

per Benson, Don M, Panzner, Kathryn, Hamadani, Mehdi, Hofmeister, Craig C, Bakan, Courtney E, Smith, Megan K, Elder, Pat, Krugh, David, O’Donnell, Lynn, Devine, Steven M
Publicat 2010

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

per Benson, Don M., Hofmeister, Craig C., Padmanabhan, Swaminathan, Suvannasankha, Attaya, Jagannath, Sundar, Abonour, Rafat, Bakan, Courtney, Andre, Pascale, Efebera, Yvonne, Tiollier, Jérôme, Caligiuri, Michael A., Farag, Sherif S.
Publicat 2012

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

per Collins, Shauna M., Bakan, Courtney E., Swartzel, Gina D., Hofmeister, Craig C., Efebera, Yvonne A., Kwon, Hakju, Starling, Gary C., Ciarlariello, David, Bhaskar, Shakthi, Briercheck, Edward L., Hughes, Tiffany, Yu, Jianhua, Rice, Audie, Benson, Don M.
Publicat 2013

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

per Benson, Don M., Bakan, Courtney E., Zhang, Shuhong, Collins, Shauna M., Liang, Jing, Srivastava, Shivani, Hofmeister, Craig C., Efebera, Yvonne, Andre, Pascale, Romagne, Francois, Bléry, Mathieu, Bonnafous, Cécile, Zhang, Jianying, Clever, David, Caligiuri, Michael A., Farag, Sherif S.
Publicat 2011

The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity

per Young Gregory S, Fossey Stacey L, Hoyt Dale G, Lin Jiayuh, Abdelhamid Dalia, Schwartz Eric B, Benson Don M, Bakan Courtney, Yui Jennifer, Li Chenglong, Fuchs James R, Bill Matthew A, Carson William E, Li Pui-Kai, Lesinski Gregory B
Publicat 2010-06-01

The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity

per Bill, Matthew A, Fuchs, James R, Li, Chenglong, Yui, Jennifer, Bakan, Courtney, Benson, Don M, Schwartz, Eric B, Abdelhamid, Dalia, Lin, Jiayuh, Hoyt, Dale G, Fossey, Stacey L, Young, Gregory S, Carson, William E, Li, Pui-Kai, Lesinski, Gregory B
Publicat 2010

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody

per Benson, Don M., Bakan, Courtney E., Mishra, Anjali, Hofmeister, Craig C., Efebera, Yvonne, Becknell, Brian, Baiocchi, Robert A., Zhang, Jianying, Yu, Jianhua, Smith, Megan K., Greenfield, Carli N., Porcu, Pierluigi, Devine, Steven M., Rotem-Yehudar, Rinat, Lozanski, Gerard, Byrd, John C., Caligiuri, Michael A.
Publicat 2010

Recombinant Interleukin-2 in Patients Aged Younger Than 60 Years With Acute Myeloid Leukemia in First Complete Remission: Results From Cancer and Leukemia Group B 19808

per Kolitz, Jonathan E., George, Stephen L., Benson, Don M., Maharry, Kati, Marcucci, Guido, Vij, Ravi, Powell, Bayard L., Allen, Steven L., DeAngelo, Daniel J., Shea, Thomas C., Stock, Wendy, Bakan, Courtney E., Hars, Vera, Hoke, Eva, Bloomfield, Clara D., Caligiuri, Michael A., Larson, Richard A.
Publicat 2013